METABOLOMIC AND LIPIDOMIC ANALYSIS OF PATIENTS WITH PRESUMED METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) TREATED WITH THE SELECTIVE GLUCOCORTICOID RECEPTOR MODULATOR MIRICORILANT

被引：0
|
作者：
Kowdley, Kris [1 ]
Noureddin, Mazen [2 ]
Parks, Elizabeth [3 ]
Botbyl, Jeffrey [4 ]
Monibas, Rafael Mayoral [4 ]
Wadekar, Subhagya [4 ]
Espinueva, Aprille [4 ]
Juneja, Kavita [4 ]
Schwab, Andrew [5 ]
Alkhouri, Naim [6 ]
机构：
[1] Liver Inst Northwest, Seattle, WA USA
[2] Houston Methodist Hosp, Houston, TX USA
[3] Univ Missouri, Columbia, MO USA
[4] Corcept Therapeut Inc, Menlo Pk, CO USA
[5] Metabolon, Durham, NC USA
[6] Arizona Liver Hlth, Phoenix, AZ USA
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1637
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Pharmacokinetics of the selective glucocorticoid receptor modulator miricorilant in healthy volunteers and patients with presumed metabolic dysfunction-associated steatohepatitis (MASH)
    Custodio, Joseph M.
    Donaldson, Kirsteen
    Kunta, Jeevan
    Juneja, Kavita
    Alkhouri, Naim
    Hunt, Hazel J.
    JOURNAL OF HEPATOLOGY, 2024, 80 : S613 - S614
  • [2] Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
    Do, Albert
    Zahrawi, Frhaan
    Mehal, Wajahat Z.
    NATURE REVIEWS DRUG DISCOVERY, 2025, 24 (03) : 171 - 189
  • [3] Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
    Do, Albert
    Zahrawi, Frhaan
    Mehal, Wajahat Z.
    NATURE REVIEWS DRUG DISCOVERY, 2024,
  • [4] Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
    Albert Do
    Frhaan Zahrawi
    Wajahat Z. Mehal
    Nature Reviews Drug Discovery, 2025, 24 (3) : 171 - 189
  • [5] Silent MASH: A Case of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Normal Aminotransferases
    Li, Elizabeth
    Vallabhaneni, Manasa
    Lin, Joanne
    Hogan, Carolyn
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S2778 - S2778
  • [6] Untargeted lipidomic analysis of metabolic dysfunction-associated steatohepatitis in women with morbid obesity
    Bertran, Laia
    Capellades, Jordi
    Abello, Sonia
    Richart, Cristobal
    PLOS ONE, 2025, 20 (03):
  • [7] Metabolic dysfunction-associated steatohepatitis (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) require urgent attention by primary care physicians and endocrinologists
    Mauricio, Didac
    Escalada, Javier
    Perez, Antonio
    Romero-Gomez, Manuel
    Cusi, Kenneth
    Younoussi, Zobair M.
    Lazarus, Jeffrey V.
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2024, 71 (04): : 149 - 151
  • [8] Found in translation-Fibrosis in metabolic dysfunction-associated steatohepatitis (MASH)
    Wang, Shuang
    Friedman, Scott L.
    SCIENCE TRANSLATIONAL MEDICINE, 2023, 15 (716)
  • [9] Thyroid hormone receptor-b analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)
    Ratziu, Vlad
    Scanlan, Thomas S.
    Bruinstroop, Eveline
    JOURNAL OF HEPATOLOGY, 2025, 82 (02) : 375 - 387
  • [10] Metabolic issues in patients with metabolic dysfunction-associated steatohepatitis (MASH) and their impact on MASH recurrence following liver transplantation: A narrative review
    Alnimer, Lynna
    Arellano, Diego
    Brombosz, Elizabeth
    Noureddin, Mazen
    LIVER TRANSPLANTATION, 2024,
12345